Search results
Showing 811 to 825 of 1512 results for patients and public
Awaiting development Reference number: GID-TA11743 Expected publication date: TBC
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]
Awaiting development Reference number: GID-TA11667 Expected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Awaiting development Reference number: GID-TA11692 Expected publication date: TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Awaiting development Reference number: GID-TA11755 Expected publication date: TBC
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Awaiting development Reference number: GID-TA11741 Expected publication date: TBC
Awaiting development Reference number: GID-TA11753 Expected publication date: TBC
In development Reference number: GID-TA11229 Expected publication date: TBC
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]
Awaiting development Reference number: GID-TA11325 Expected publication date: TBC
Extracorporeal shockwave therapy for Achilles tendinopathy (HTG426)
Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
Pharyngeal electrical stimulation for neurogenic dysphagia (HTG709)
Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.
View recommendations for HTG709Show all sections
In development Reference number: GID-TA11356 Expected publication date: TBC
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.